



Attorney Docket No.: 5778.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No.: EL443984197US
Date of Deposit: January 13, 2000



Sir:

This is a request for filing a **continuation-in-part** application under 37 C.F.R.

1.53(b) of

Applicant(s): Berka *et al.*

Title: Methods For Producing Polypeptides In Cyclohexadepsipeptide-Deficient
Cells

51 pages of specification 10 sheets of formal drawings 11 pages of Sequence Listing
3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$690.00
Total Claims: 20 - 20 = 0 x 18 =	\$0
Independent Claims: 3 - 3 = 0 x 78 =	\$0
Total Fee:	\$690.00

This application is a continuation-in-part of application no. 09/229,862 filed on
January 13, 1999 and claims priority under 35 U.S.C. 119, the contents of which are fully
incorporated herein by reference.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North
America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North
America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: January 13, 2000

Respectfully submitted,

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, New York 10017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
"Methods For Producing Polypeptides In Cyclohexadepsipeptide-
Deficient Cells"
Applicants: Berka *et al.*

Sir:

Express Mail Label No.: EL443984197US

Date of Deposit: January 13, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Assignment
6. Recordation
7. Sequence Listing
8. Sequence Listing Diskette
9. Verified Statement

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Seleste A. Buriani

(Name of person mailing papers or fees)

Seleste A. Buriani

(Signature of person mailing papers or fees)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

00443984197US